Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
42
RBOT Quote, Financials, Valuation and Earnings
Last price:
$2.41
Seasonality move
:
-12.94%
Day range:
$2.36 - $2.65
52-week range:
$2.36 - $18.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.04x
Volume:
150.4K
Avg. volume:
134.1K
1-year change:
-82.61%
Market cap:
$14.7M
Revenue:
--
EPS (TTM):
-$9.04
Analysts' Opinion
-
Consensus RatingVicarious Surgical, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.00, Vicarious Surgical, Inc. has an estimated upside of 102.43% from its current price of $2.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing -102.43% downside risk from its current price of $2.47.
Fair Value
-
According to the consensus of 1 analyst, Vicarious Surgical, Inc. has 102.43% upside to fair value with a price target of $5.00 per share.
RBOT vs. S&P 500
-
Over the past 5 trading days, Vicarious Surgical, Inc. has underperformed the S&P 500 by -11.82% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vicarious Surgical, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vicarious Surgical, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Vicarious Surgical, Inc. reported revenues of --.
Earnings Growth
-
Vicarious Surgical, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Vicarious Surgical, Inc. reported earnings per share of -$1.86.
Enterprise value:
14.1M
EV / Invested capital:
0.52x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.7M
Return On Assets:
-97.93%
Net Income Margin (TTM):
--
Return On Equity:
-152.42%
Return On Invested Capital:
-110.17%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$2.3M | -$2.1M | -$1.7M | -$507K | -$352K | |
| Operating Income | -$85.7M | -$67.1M | -$55.7M | -$17.8M | -$11.5M | |
| EBITDA | -$83.4M | -$65M | -$54.1M | -$17.2M | -$11.2M | |
| Diluted EPS | -$0.53 | -$5.66 | -$9.04 | -$2.90 | -$1.86 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $191.2M | $131.3M | $113.4M | $64M | $15.1M | |
| Total Assets | $193.4M | $150.7M | $132.1M | $80.6M | $29.3M | |
| Current Liabilities | $3.1M | $11.7M | $7.8M | $8.6M | $3.2M | |
| Total Liabilities | $135.1M | $41.7M | $24.2M | $22.7M | $15.3M | |
| Total Equity | $58.3M | $109M | $107.9M | $57.9M | $14.1M | |
| Total Debt | $1.5M | $15.9M | $14.1M | $12.9M | $11.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$69.5M | -$49.7M | -$47.6M | -$12.7M | -$10.4M | |
| Cash From Investing | -$51.9M | -$2.6M | $43.5M | -$503.1K | $9.7M | |
| Cash From Financing | $53.5M | $92.8K | $72.9K | -- | $25.9K | |
| Free Cash Flow | -$71.2M | -$50.7M | -$47.7M | -$12.7M | -$10.5M | |
RBOT
Sector
Market Cap
$14.7M
$28M
Price % of 52-Week High
13.02%
51.86%
Dividend Yield
0%
0%
Shareholder Yield
0.66%
-1.4%
1-Year Price Total Return
-82.61%
-19%
Beta (5-Year)
1.510
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.78
200-day SMA
Sell
Level
$6.77
Bollinger Bands (100)
Sell
Level
3.68 - 7.66
Chaikin Money Flow
Sell
Level
-3.3M
20-day SMA
Sell
Level
$2.78
Relative Strength Index (RSI14)
Sell
Level
34.18
ADX Line
Sell
Level
16.26
Williams %R
Buy
Level
-91.5385
50-day SMA
Sell
Level
$4.38
MACD (12, 26)
Sell
Level
-0.45
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Sell
Level
-3.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.2904)
Sell
CA Score
(Annual)
Level (-2.4196)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.6794)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vicarious Surgical, Inc. a blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It also designs surgical robotics. The company was founded by Adam Sachs, Sammy Khalifa, and Barry Greene on May 1, 2014 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, RBOT has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RBOT average analyst price target in the past 3 months is $5.00.
-
Where Will Vicarious Surgical, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vicarious Surgical, Inc. share price will rise to $5.00 per share over the next 12 months.
-
What Do Analysts Say About Vicarious Surgical, Inc.?
Analysts are divided on their view about Vicarious Surgical, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vicarious Surgical, Inc. is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Vicarious Surgical, Inc.'s Price Target?
The price target for Vicarious Surgical, Inc. over the next 1-year time period is forecast to be $5.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RBOT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vicarious Surgical, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of RBOT?
You can purchase shares of Vicarious Surgical, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vicarious Surgical, Inc. shares.
-
What Is The Vicarious Surgical, Inc. Share Price Today?
Vicarious Surgical, Inc. was last trading at $2.41 per share. This represents the most recent stock quote for Vicarious Surgical, Inc.. Yesterday, Vicarious Surgical, Inc. closed at $2.47 per share.
-
How To Buy Vicarious Surgical, Inc. Stock Online?
In order to purchase Vicarious Surgical, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RBOT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RBOT
Sector
P/E ratio
--
24.31x
PEG ratio
0.00x
-0.01x
P/B ratio
1.04x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
RBOT
Sector
Revenue growth
--
4.6%
Earnings growth
35.9%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$2.33
-$0.20
Profitability
RBOT
Sector
Profitability FY 2024
-$2.1M
$3.5M
Return on invested capital
-110.17%
-31.66%
Return on assets
-97.93%
-27.84%
Return on equity
-152.42%
-37.28%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
16
Estimated Next Earnings Date
Feb
11
Balance Sheet
RBOT
Sector
Total cash
$13.4M
$26.8M
Short term investments
$39.4M
$26M
Total assets
$67.7M
$78.7M
Long term debt
$11.5M
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 18.2% over the past day.
Sell
33
ZBIO alert for Dec 16
Zenas BioPharma, Inc. [ZBIO] is up 13.35% over the past day.
Sell
38
HUT alert for Dec 16
Hut 8 Corp. [HUT] is up 3.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
